Actively Recruiting
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Led by National Taiwan University Hospital · Updated on 2024-12-18
20
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are studying patients with amyotrophic lateral sclerosis (ALS) who have an autoantibody against NRIP, which may cause harmful effects depending on its levels. This study evaluates the potential benefits of plasmapheresis, a procedure that removes this autoantibody from the blood, in this specific group of ALS patients. The trial is interventional and sponsored by National Taiwan University Hospital. Participants will receive regular plasmapheresis treatment aimed at removing the anti-NRIP autoantibody. The study focuses on ALS patients with different antibody titers and monitors changes in their condition before and after the intervention. There is no placebo group, and the treatment is delivered directly through the plasmapheresis procedure. During the study, participants will undergo serial examinations and follow-up visits to assess various measures including ALS functional rating scale scores over several time points, lung function, muscle nerve responses, and antibody levels. Safety is also monitored by recording any adverse effects during and after the plasmapheresis treatment, with the overall participation spanning at least six months.
CONDITIONS
Brief Title
Plasmapheresis in Amyotrophic Lateral Sclerosis With Autoantibody Against NRIP
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with amyotrophic lateral sclerosis (ALS) aged more than 20 years who have plasma anti-NRIP autoantibody
- Agree to receive plasmapheresis intervention
- Agree to participate in the trial and receive serial examinations and follow-up
You will not qualify if you...
- Patients without plasma anti-NRIP autoantibody
- Patients requiring permanent ventilator support for ALS progression
- Unable to receive plasmapheresis or trial-related examinations
- Currently pregnant
- Blood fibrinogen level less than 50 mg/dl
- Specific ALS subtypes including primary lateral sclerosis, progressive muscular atrophy, flail arm syndrome, or flail leg syndrome
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive regular plasmapheresis to remove anti-NRIP autoantibody as part of the intervention.
Visits on days 0, 30, 90, and 180
Trial Site Locations
Total: 1 location
1
National Taiwan University Hospital
Taipei, Taiwan, 100
Actively Recruiting
Research Team
L
Li-Kai Tsai, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here